RIZE Clinical Trial for Individuals with Hyperinsulinism

RIZE Clinical Trial for Individuals with Hyperinsulinism

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is no longer recruiting.

Description
Our team is working on a clinical drug trial that involves giving you a study drug that is not FDA-approved called RZ358. The goal of the trial is to test the study drug safety, how your body processes the drug, how the drug affects your body, and see if it can increase your blood sugar. If you agree to take part, your participation will last for up to 27 weeks and include 4 weeks of screening, 8 weeks of treatment, and a 15 week follow-up period. It is possible that treatment with the study drug infusions may improve your blood sugar levels and/or reduce the use of other medication(s) to prevent hypoglycemia. For more information, contact us at HIResearch@email.chop.edu.

Eligibility and criteria
IRB Number:
20-017657
Eligible age range:
12 years - 45 years
Clinical trial phase:
Phase II
Official title:
An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism

What to expect

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.